Enveric Biosciences Past Earnings Performance
Past criteria checks 0/6
Enveric Biosciences's earnings have been declining at an average annual rate of -24.9%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually.
Key information
-24.9%
Earnings growth rate
17.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -196.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Enveric Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -11 | 6 | 4 |
| 31 Mar 24 | 0 | -15 | 8 | 6 |
| 31 Dec 23 | 0 | -17 | 9 | 7 |
| 30 Sep 23 | 0 | -23 | 10 | 8 |
| 30 Jun 23 | 0 | -23 | 13 | 8 |
| 31 Mar 23 | 0 | -19 | 12 | 8 |
| 31 Dec 22 | 0 | -19 | 12 | 8 |
| 30 Sep 22 | 0 | -52 | 18 | 9 |
| 30 Jun 22 | 0 | -52 | 16 | 8 |
| 31 Mar 22 | 0 | -50 | 16 | 7 |
| 31 Dec 21 | 0 | -49 | 20 | 5 |
| 30 Sep 21 | 0 | -11 | 14 | 2 |
| 30 Jun 21 | 0 | -9 | 13 | 1 |
| 31 Mar 21 | 0 | -9 | 11 | 0 |
| 31 Dec 20 | 0 | -7 | 5 | 0 |
| 30 Sep 20 | 0 | -3 | 2 | 0 |
| 30 Jun 20 | 0 | -3 | 2 | 0 |
| 31 Mar 20 | 0 | -3 | 3 | 0 |
| 31 Dec 19 | 0 | -2 | 2 | 0 |
| 30 Sep 19 | 0 | -3 | 3 | 0 |
| 31 Dec 18 | 0 | -2 | 2 | 0 |
Quality Earnings: SLZA is currently unprofitable.
Growing Profit Margin: SLZA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SLZA is unprofitable, and losses have increased over the past 5 years at a rate of 24.9% per year.
Accelerating Growth: Unable to compare SLZA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLZA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: SLZA has a negative Return on Equity (-195.97%), as it is currently unprofitable.